GSK-690693

Research use only, not for human use.

A potent, ATP competitive, pan-AKT inhibitor with IC50 of 2, 13, and 9 nM against AKT1, 2, and 3, respectively.

A potent, ATP competitive, pan-AKT inhibitor with IC50 of 2, 13, and 9 nM against AKT1, 2, and 3, respectively; also inhibits additional members of the AGC kinase family (PKA, PrkX, and PKC isozymes, IC50s<100 nM); dose-dependently reduces the phosphorylation GSK3 beta, PRAS40 and Forkhead, inhibits proliferation and induces apoptosis in a subset of tumor cells; exhibits significant antitumor activity in mice model.Blood Cancer Phase 1 Discontinued

GSK 690693;GSK690693

Cytoskeleton/Cell Adhesion Molecules

Akt

Akt1;Akt3;PKCη;PKCθ;PrkX

Cancer

Blood cancer

937174-76-0

425.48

C21H27N7O3

>98% (HPLC)

10 mM in DMSO

CC(O)(C)C#CC1=NC=C(OC[C@@H]2CNCCC2)C3=C1N=C(C4=NON=C4N)N3CC

3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-

(-20℃)

With Ice Pack

≥ 2 years